These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Biomarker research in Parkinson's disease: objective measures needed for patient stratification in future cause-directed trials. Schlossmacher MG; Mollenhauer B Biomark Med; 2010 Oct; 4(5):647-50. PubMed ID: 20945977 [No Abstract] [Full Text] [Related]
6. Common mutations in the LRRK2 exon 41 are not responsible for essential tremor in Italian patients. Vitale C; Ciotti P; Gulli R; Bellone E; Scaglione C; Abbruzzese G; Martinelli P; Barone P; Mandich P Parkinsonism Relat Disord; 2009 Feb; 15(2):162-3. PubMed ID: 18556235 [No Abstract] [Full Text] [Related]
7. How much does dardarin contribute to Parkinson's disease? Brice A Lancet; 2005 Jan 29-Feb 4; 365(9457):363-4. PubMed ID: 15680438 [No Abstract] [Full Text] [Related]
8. Genetics of Parkinson's disease: LRRK2 on the rise. Brice A Brain; 2005 Dec; 128(Pt 12):2760-2. PubMed ID: 16311269 [No Abstract] [Full Text] [Related]
9. The LRRK2 I2012T, G2019S and I2020T mutations are not common in patients with essential tremor. Deng H; Le W; Davidson AL; Xie W; Jankovic J Neurosci Lett; 2006 Oct; 407(2):97-100. PubMed ID: 16939701 [TBL] [Abstract][Full Text] [Related]
10. Translational research in neurology and neuroscience 2011: movement disorders. Klein C; Krainc D; Schlossmacher MG; Lang AE Arch Neurol; 2011 Jun; 68(6):709-16. PubMed ID: 21320985 [TBL] [Abstract][Full Text] [Related]
11. Movement disorders in 2018: tackling this evil at the roots. Vidailhet M Lancet Neurol; 2019 Jan; 18(1):8-10. PubMed ID: 30563685 [No Abstract] [Full Text] [Related]
12. The importance of LRRK2 mutations in Parkinson disease. Schapira AH Arch Neurol; 2006 Sep; 63(9):1225-8. PubMed ID: 16966498 [No Abstract] [Full Text] [Related]
13. Neuromodulation for movement disorders. Dallapiazza R; McKisic MS; Shah B; Elias WJ Neurosurg Clin N Am; 2014 Jan; 25(1):47-58. PubMed ID: 24262899 [TBL] [Abstract][Full Text] [Related]
14. Leucine-rich repeat kinase 2: a new player with a familiar theme for Parkinson's disease pathogenesis. Li C; Beal MF Proc Natl Acad Sci U S A; 2005 Nov; 102(46):16535-6. PubMed ID: 16275903 [No Abstract] [Full Text] [Related]
15. Leucine-rich repeat kinase 2 (LRRK2) mutations in a Swedish Parkinson cohort and a healthy nonagenarian. Carmine Belin A; Westerlund M; Sydow O; Lundströmer K; Håkansson A; Nissbrandt H; Olson L; Galter D Mov Disord; 2006 Oct; 21(10):1731-4. PubMed ID: 16817197 [TBL] [Abstract][Full Text] [Related]
16. LRRK2 mutations and Parkinsonism. Albrecht M Lancet; 2005 Apr 2-8; 365(9466):1230. PubMed ID: 15811455 [No Abstract] [Full Text] [Related]
17. LRRK2 mutations and Parkinsonism. Toft M; Mata IF; Kachergus JM; Ross OA; Farrer MJ Lancet; 2005 Apr 2-8; 365(9466):1229-30. PubMed ID: 15811454 [No Abstract] [Full Text] [Related]
18. [LRRK2: a gene belonging to the ROCO family is implicated in the Parkinson's disease]. Lesage S; Leutenegger AL; Brice A Med Sci (Paris); 2005 Dec; 21(12):1015-7. PubMed ID: 16324633 [No Abstract] [Full Text] [Related]
19. Movement disorders in pregnancy. Ba F; Miyasaki JM Handb Clin Neurol; 2020; 172():219-239. PubMed ID: 32768090 [TBL] [Abstract][Full Text] [Related]
20. [Thalamic deep brain stimulation therapy: a guide to stereotactic brain operations]. Sugiyama K No Shinkei Geka; 2004 May; 32(5):531-9. PubMed ID: 15287493 [No Abstract] [Full Text] [Related] [Next] [New Search]